Pfizer (HAM:PFE) Other Net Income (Loss): €10 Mil (TTM As of Mar. 2026)


HAM:PFE Pfizer Inc HAM:PFE
74 GF Score
Price €21.83
GF Value €23.01
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Other Net Income (Loss)?

Pfizer HAM:PFE -0.27% 74 Other Net Income (Loss) is €10 Mil as of Mar. 2026. GuruFocus rates HAM:PFE with a GF Score™ of 74/100 and a GF Value™ of €23.01 (Fairly Valued). The stock has 5 warning signs investors should review.

Pfizer's Other Net Income (Loss) for the three months ended in Mar. 2026 was €-12 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2026 was €10 Mil.

Pfizer's quarterly Other Net Income (Loss) increased from Sep. 2025 (€-0 Mil) to Dec. 2025 (€0 Mil) but then declined from Dec. 2025 (€0 Mil) to Mar. 2026 (€-12 Mil).

Pfizer's annual Other Net Income (Loss) increased from Dec. 2023 (€-14 Mil) to Dec. 2024 (€11 Mil) and increased from Dec. 2024 (€11 Mil) to Dec. 2025 (€22 Mil).

Pfizer Other Net Income (Loss) Related Terms

Pfizer Other Net Income (Loss) Historical Data

* Premium members only.

The historical data trend for Pfizer's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Other Net Income (Loss) Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -384.97 5.66 -13.76 10.50 22.20

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.92 21.67 -0.00 0.00 -12.11
HAM:PFE
74GF Score
Pfizer Inc HAM:PFE
Other Net Income (Loss) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Net Income (Loss) of €10 Mil mean?
Pfizer (HAM:PFE) has a Other Net Income (Loss) of €10 Mil as of Mar. 2026.
Is Pfizer's Other Net Income (Loss) too high?
Pfizer's current Other Net Income (Loss) is €10 Mil. Overall, Pfizer has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Other Net Income (Loss) compare to GILD and BMY?
Pfizer's Other Net Income (Loss) of €10 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Net Income (Loss) for a Drug Manufacturers company?
A good Other Net Income (Loss) depends on the Drug Manufacturers industry context. However, Other Net Income (Loss) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Net Income (Loss) mean?
A high Other Net Income (Loss) can signal that a stock is expensive relative to its fundamentals. Pfizer's current Other Net Income (Loss) is €10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (HAM:PFE) is currently considered Fairly Valued. The stock's GF Value™ is €23.01, compared to a current price of €21.83 — trading 5.1% below its estimated fair value. The current Other Net Income (Loss) is €10 Mil. Pfizer's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Net Income (Loss) calculated?
Other Net Income (Loss) is calculated from a company's financial statements. For Pfizer (HAM:PFE), the current Other Net Income (Loss) is €10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (HAM:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of €21.83 is trading 5.1% below its estimated GF Value™ of €23.01. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for HAM:PFE:

  • Other Net Income (Loss): €10 Mil
  • GF Value™: €23.01 vs. price of €21.83 (5.1% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the HAM:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
74GF Score

Get the complete analysis for HAM:PFE

Other Net Income (Loss) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.83
Price
€23.01
GF Value